1. Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, Alkhalaf M. P 53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol. 2011;28(3):709–15.
2. Bayever E, Iversen P, Smith L, Spinolo J, Zon G. Guest editorial: systemic human antisense therapy begins. Antisense Res Dev. 1992a;2:109–10.
3. Bayever E, Haines K, Iversen P, Spinolo J, Kay D, Smith L. Antisense p 53 oligodeoxynucleotides as potential human anti-leukemic agents. Am Assoc Cancer Res. 1992b.
4. Bayever E, Cornish K, Iversen P, Smith L, Spinolo J, Zon G. In vitro and In vivo studies with a human p 53 antisense oligonucleotide phophorothioate. INSERM/NIH Conference on “Antisense Oligonucleotides and Ribonucleases H” in Arcachon, France. 1992c.
5. Bayever E, Haines K, Iversen PL, Ruddon RW, Pirruccello SJ, Mountjoy CP, Arneson MA, Smith LJ. Selective cytotoxicity of human leukemic Myeloblasts produced by oligodeoxyribonucleic phosphorothioate complementary to p 53 nucleotide sequences. Leuk Lymphoma. 1993a;12:223–31.